Annual report pursuant to Section 13 and 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.24.2.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
11 Months Ended 12 Months Ended
Apr. 01, 2024
Apr. 30, 2024
Apr. 30, 2023
Indefinite-Lived Intangible Assets [Line Items]      
Intangible asset impairment   $ 2,000,000 $ 0
Stock Repurchased During Period, Value   28,479,593 13,560,623
Accrual for Taxes Other than Income Taxes, Current   281,976 58,096
Research and development expenses   407,431 468,536
Federal deposit insurance amount   250,000  
Cash uninsured amount   $ 6,910,000 $ 279,000
Common Stock [Member]      
Indefinite-Lived Intangible Assets [Line Items]      
Stock Repurchased During Period, Shares   8,826,356 4,808,098
Stock Repurchased During Period, Value   $ 28,479,593 $ 13,560,623
SG Austria [Member]      
Indefinite-Lived Intangible Assets [Line Items]      
Asset Impairment Charges $ 1,572,191    
Diabetes License [Member]      
Indefinite-Lived Intangible Assets [Line Items]      
Intangible asset impairment 2,000,000    
Cell In A Box Technology [Member]      
Indefinite-Lived Intangible Assets [Line Items]      
Intangible asset impairment $ 0    
Cell In A Box [Member]      
Indefinite-Lived Intangible Assets [Line Items]      
Intangible assets   1,549,427  
Diabetes License [Member]      
Indefinite-Lived Intangible Assets [Line Items]      
Intangible assets   $ 2,000,000